Earlobe sarcoidosis

Earlobe sarcoidosis

Authors

  • A.D.M. Vorselaars
  • R.G.M. Keijsers
  • J.C. Grutters, et al.

Keywords:

Sarcoidosis, 18F-FDG-PET, Infliximab, TNF-α mAb

Abstract

Background: Infliximab, a TNF-α blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. Design: Case-report. Results and conclusions: A patient with severe earlobe sarcoidosis, treated with infliximab, is presented. This case shows that even relatively small extrapulmonary localisations of sarcoidosis can be visualised by 18F-FDG-PET, and that a decrease of FDG-uptake correlates well with clinical improvement on infliximab treatment.

Downloads

Published

01-06-2012

Issue

Vol. 29 No. 1 (2012)

Section

Case Reports

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

1.
Vorselaars A, Keijsers R, Grutters, et al. J. Earlobe sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2012 Jun. 1 [cited 2025 Jun. 22];29(1):55-7. Available from: https://mattioli1885journals.com/index.php/sarcoidosis/article/view/2522